IL2 and neuroblastoma: In this study, we examined patients with histologically confirmed Stage IV neuroblastoma at relapse post standard therapies, who were treated between 2010 and 2017 in a prospective multicenter Phase I/II trial (NCT02258815) with a combination of haploidentical HSCT and consecutive GD2 dinutuximab beta (ch14.18) mAb therapy administered with IL-2.